Genocea Biosciences (GNCA) PT Lowered to $15 at Needham & Company

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/21/2026

1. SPCX
2. NVDA
3. NFLX
4. ISRG
5. TSLA
6. META
7. RTX
8. SMCI
9. GOOGL
10. S

Go back to Genocea Biosciences (GNCA) PT Lowered to $15 at Needham & Company

Genocea Announces Top-Line Results from Phase 2a Trial for Universal Pneumococcal Vaccine Candidate GEN-004

October 19, 2015 7:00 AM EDT

- Consistent Reductions vs. Placebo in Rate and Density of Colonization; Not Statistically Significant -

- Development Suspended Pending Further Review of Data and Potential Paths Forward -

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing T cell-directed vaccines and immunotherapies, today announced that top-line results from a Phase 2a clinical trial for GEN-004, its universal vaccine candidate against pneumococcus, showed consistent reductions versus placebo in the pre-specified endpoints of the rate and density of colonization, but that neither of the endpoints achieved... More